nach oben

Current Cardiology Reports

Erschienen in:

03.07.2023 | Cardio-Oncology (LA Baldassarre, Section Editor)

An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors

verfasst von: Judah M. Ellison, Anju Nohria

Erschienen in: Current Cardiology Reports | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Immune checkpoint inhibitor (ICI) therapy activates the host immune system to promote tumor cell death. This activation of the immune system can lead to off-target immune-related adverse events (irAEs). There is an established link between inflammation and atherosclerosis. The purpose of this manuscript is to review the existing body of literature discussing the potential association between ICI treatment and atherosclerosis.

Recent Findings

Pre-clinical studies suggest that ICI therapy may lead to T-cell-mediated progression of atherosclerosis. Recent retrospective clinical studies have shown higher rates of myocardial infarction and stroke with ICI therapy, particularly in patients with pre-existing cardiovascular risk factors. Additionally, small observational cohort studies have used imaging modalities to demonstrate higher rates of atherosclerotic progression with ICI treatment.

Summary

Early pre-clinical and clinical evidence suggests an association between ICI treatment and the progression of atherosclerosis. However, these findings are preliminary, and adequately powered prospective studies are needed to demonstrate a conclusive association. As ICI therapy is increasingly used to treat a variety of solid tumors, it is important to evaluate and mitigate the potential adverse atherosclerotic effects of ICI treatment.

Hodi SF, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.CrossRefPubMedPubMedCentral

Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022;86(Pt 3):137–50. https://doi.org/10.1016/j.semcancer.2022.03.014.CrossRefPubMed

Suero-Abreu GA, Zanni MV, Neilan TG. Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology State-of-the-Art Review. J Am Coll Cardiol CardioOnc. 2022;4(5):598–615. https://doi.org/10.1016/j.jaccao.2022.11.011.CrossRef

Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–92. https://doi.org/10.1016/s1470-2045(17)30616-2.CrossRefPubMed

Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–65. https://doi.org/10.1016/s1470-2045(15)70054-9.CrossRefPubMedPubMedCentral

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/nejmoa1606774.CrossRefPubMed

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. https://doi.org/10.1126/science.aar4060.CrossRefPubMedPubMedCentral

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68. https://doi.org/10.1056/nejmra1703481.CrossRefPubMed

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma [published correction appears in N Engl J Med. 2018 Nov 29;379(22):2185]. N Engl J Med. 2017;377(14):1345–1356. https://doi.org/10.1056/nejmoa1709684.

10.

Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0.CrossRefPubMed

11.

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. https://doi.org/10.1016/j.jacc.2018.02.037.CrossRefPubMedPubMedCentral

12.

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https://doi.org/10.1016/s0140-6736(18)30533-6.CrossRefPubMedPubMedCentral

13.

Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315–27. https://doi.org/10.1161/circresaha.118.313591.CrossRefPubMedPubMedCentral

14.

Vuong JT, Stein-Merlob AF, Nayeri A, Sallam T, Neilan TG, Yang EH. Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(6):577–93. https://doi.org/10.1016/j.jacc.2021.11.048.CrossRefPubMedPubMedCentral

15.

Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92(9):3893–3897. https://doi.org/10.1073/2Fpnas.92.9.3893.

16.

Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991;11(5):1223–30. https://doi.org/10.1161/01.atv.11.5.1223.CrossRefPubMed

17.

McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6(6):410–7. https://doi.org/10.1038/nrcardio.2009.57.CrossRefPubMed

18.

Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74. https://doi.org/10.1038/nature01323.CrossRefPubMed

19.

Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12(2):178–80. https://doi.org/10.1038/nm1343.CrossRefPubMed

20.

Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/nejmoa1707914.CrossRefPubMed

21.

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. https://doi.org/10.1016/j.jacc.2012.10.027.CrossRefPubMed

22.

Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. https://doi.org/10.1056/nejmoa1912388.CrossRefPubMed

23.

Baitsch L, Baumgaertner P, Devêvre E, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350–60. https://doi.org/10.1172/jci46102.CrossRefPubMedPubMedCentral

24.

Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295–307. https://doi.org/10.1038/nri1806.CrossRefPubMed

25.

Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52. https://doi.org/10.1016/j.immuni.2018.03.014.CrossRefPubMedPubMedCentral

26.

Dietel B, Cicha I, Voskens CJ, Verhoeven E, Achenbach S, Garlichs CD. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis. 2013;230(1):92–9. https://doi.org/10.1016/j.atherosclerosis.2013.06.014.CrossRefPubMed

27.

Poels K, van Leent MMT, Reiche ME, et al. Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice. Cells. 2020;9(9):1987. https://doi.org/10.3390/cells9091987.CrossRefPubMedPubMedCentral

28.

Matsumoto T, Sasaki N, Yamashita T, et al. Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2016;36(6):1141–51. https://doi.org/10.1161/atvbaha.115.306848.CrossRefPubMed

29.

Seijkens TTP, van Tiel CM, Kusters PJH, Atzler D, Soehnlein O, Zarzycka B, Aarts SABM, Lameijer M, Gijbels MJ, Beckers L, et al. Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. J Am Coll Cardiol. 2018;71(5):527–42. https://doi.org/10.1016/j.jacc.2017.11.055.CrossRefPubMedPubMedCentral

30.

Ewing MM, Karper JC, Abdul S, et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol. 2013;168(3):1965–74. https://doi.org/10.1016/j.ijcard.2012.12.085.CrossRefPubMed

31.

Ma K, Lv S, Liu B, et al. CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE−/− mice. Cardiovasc Res. 2013;97(2):349–59. https://doi.org/10.1093/cvr/cvs330.CrossRefPubMed

32.

Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest. 2007;117(10):2974–82. https://doi.org/10.1172/jci31344.CrossRefPubMedPubMedCentral

33.

Cochain C, Chaudhari SM, Koch M, Wiendl H, Eckstein HH, Zernecke A. Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS One. 2014;9(4):e93280. https://doi.org/10.1371/journal.pone.0093280.

34.

Lee J, Zhuang Y, Wei X, et al. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol. 2009;46(2):169–76. https://doi.org/10.1016/j.yjmcc.2008.10.028.CrossRefPubMed

35.

Li SH, Chen WJ, Yan M, Shu YW, Liao YH. Expression of coinhibitory PD-L1 on CD4+CD25+FOXP3+ regulatory T cells is elevated in patients with acute coronary syndrome. Coron Artery Dis. 2015;26(7):598–603. https://doi.org/10.1097/mca.0000000000000282.CrossRefPubMed

36.

Grievink HW, Smit V, Verwilligen RAF, et al. Stimulation of the PD-1 Pathway decreases atherosclerotic lesion development in Ldlr deficient mice. Front Cardiovasc Med. 2021;8:740531. https://doi.org/10.3389/fcvm.2021.740531.

37.

Bu DX, Tarrio M, Maganto-Garcia E, et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):1100–7. https://doi.org/10.1161/atvbaha.111.224709.CrossRefPubMedPubMedCentral

38.

Tomita Y, Sueta D, Kakiuchi Y, et al. Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. Ann Oncol. 2017;28(11):2893–5. https://doi.org/10.1093/annonc/mdx326.CrossRefPubMed

39.

Ferreira M, Pichon E, Carmier D, et al. Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Target Oncol. 2018;13(4):509–15. https://doi.org/10.1007/s11523-018-0579-9.CrossRefPubMed

40.

Kwan JM, Cheng R, Feldman LE. Hepatotoxicity and recurrent NSTEMI while on pembrolizumab for metastatic giant cell bone tumor. Am J Med Sci. 2019;357(4):343–7. https://doi.org/10.1016/j.amjms.2018.11.017.CrossRefPubMed

41.

Cautela J, Rouby F, Salem JE, et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol. 2020;36(4):476–81. https://doi.org/10.1016/j.cjca.2019.11.035.CrossRefPubMed

42.

Masson R, Manthripragada G, Liu R, et al. Possible precipitation of acute coronary syndrome with immune checkpoint blockade: a case report. Perm J. 2020; 24:1. https://doi.org/10.7812/2FTPP/2F20.037.

43.

Cheng Y, Nie L, Ma W, Zheng B. Early onset acute coronary artery occlusion after pembrolizumab in advanced non-small cell lung cancer: a case report. Cardiovasc Toxicol. 2021;21(8):683–6. https://doi.org/10.1007/s12012-021-09664-z.CrossRefPubMed

44.

Gelsomino F, Fiorentino M, Zompatori M, et al. Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann Oncol. 2018;29(1):284–5. https://doi.org/10.1093/annonc/mdx718.CrossRefPubMed

45.

Lamberti G, Gelsomino F, Brocchi S, et al. New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. Ther Adv Med Oncol. 2020;12:1758835920913801. https://doi.org/10.1177/1758835920913801.CrossRefPubMedPubMedCentral

46.

Newman JL, Stone JR. Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. Cardiovasc Pathol. 2019;43:107148. https://doi.org/10.1016/j.carpath.2019.107148.

47.

Bar J, Markel G, Gottfried T, et al. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. Eur J Cancer. 2019;120:122–31. https://doi.org/10.1016/j.ejca.2019.06.021.CrossRefPubMed

48.

Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular health and outcomes in cancer patients receiving immune checkpoint Inhibitors. Am J Cardiol. 2020;125(12):1920–6. https://doi.org/10.1016/j.amjcard.2020.02.016.CrossRefPubMed

49.

Laenens D, Yu Y, Santens B, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40(29):3430–8. https://doi.org/10.1200/jco.21.01808.CrossRefPubMed

50.

Chitturi KR, Xu J, Araujo-Gutierrez R, et al. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. J Am Coll Cardiol CardioOnc. 2019;1(2):182–92. https://doi.org/10.1016/j.jaccao.2019.11.013.CrossRef

51.

Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89. https://doi.org/10.1016/S1470-2045(18)30608-9.CrossRefPubMedPubMedCentral

52.

Amiri-Kordestani L, Moslehi J, Cheng C, et al. Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. Food and Drug Administration pooled analysis. J Clin Oncol. 2018;36(15_suppl):3009. http://dx.doi.org/https://doi.org/10.1200/JCO.2018.36.15_suppl.3009.

53.

D’Souza M, Nielsen D, Svane IM, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42(16):1621–31. https://doi.org/10.1093/eurheartj/ehaa884.CrossRefPubMed

54.

Prasai A, Pokharel S, Sharma U, et al. Abstract 10520: emerging cardiovascular side effects of selective and non-selective immunotherapies in cancer patients: 2021 Results from the Global WHO Database. Circulation. 2021;144:A10520. https://doi.org/10.1161/circ.144.suppl_1.10520.CrossRef

55.

Hu YB, Zhang Q, Li HJ, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017;6(1_suppl):S8–S20. https://doi.org/10.21037/tlcr.2017.12.10.

56.

Dong M, Yu T, Tse G, et al. PD-1/PD-L1 blockade accelerates the progression of atherosclerosis in cancer patients. Curr Probl Cardiol. 2023;48(3):101527. https://doi.org/10.1016/j.cpcardiol.2022.101527.

57.

Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–19. https://doi.org/10.1001/jamaoncol.2019.0393.CrossRefPubMedPubMedCentral

58.

Solinas C, Saba L, Sganzerla P, Petrelli F. Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review. Thromb Res. 2020;196:444–53. https://doi.org/10.1016/j.thromres.2020.09.038.CrossRefPubMed

59.

• Dolladille C, Akroun J, Morice PM, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42(48):4964–4977. https://doi.org/10.1093/eurheartj/ehab618. This study is the largest meta-analysis to-date on this topic, and findings support an association between ICI therapy and increased risk for atherosclerotic cardiovascular irAEs.

60.

Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–87. https://doi.org/10.1056/nejmoa1110874.CrossRefPubMed

61.

Calabretta R, Hoeller C, Pichler V, et al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation. 2020;142(24):2396–8. https://doi.org/10.1161/circulationaha.120.048708.CrossRefPubMed

62.

Poels K, van Leent MMT, Boutros C, et al. Immune checkpoint inhibitor therapy aggravates T cell–driven plaque inflammation in atherosclerosis. J Am Coll Cardiol CardioOnc. 2020;2(4):599–610. https://doi.org/10.1016/j.jaccao.2020.08.007.CrossRef

63.

Mani V, Woodward M, Samber D, et al. Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study. Int J Cardiovasc Imaging. 2014;30(3):571–582. https://doi.org/10.1007/2Fs10554-014-0370-7.

64.

•• Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299–2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981. This study is the largest single-center study on this topic to-date, and its findings support an association between ICI treatment and cardiovascular AEs (including atherosclerosis progression).

65.

Kurozumi A, Sakamoto K, Nakagawa T, et al. Atherosclerotic progression is related to immune-related adverse events. 2022;63(2):293–8. https://doi.org/10.1536/ihj.21-657.CrossRef

66.

•• Zhang L, Taron J, Drobni Z, et al. Aortic plaque progression in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2020; 75(11):1715. https://doi.org/10.1016/S0735-1097(20)32342-1. This study is the only prospective study on this topic to-date, and its findings provide evidence for an increased rate of total plaque volume progression after ICI treatment.

67.

Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155. https://doi.org/10.1186/s12943-019-1091-2.CrossRefPubMedPubMedCentral

68.

Zang K, Hui L, Wang M, Huang Y, Zhu X, Yao B. TIM-3 as a prognostic marker and a potential immunotherapy target in human malignant tumors: a meta-analysis and bioinformatics validation. Front Oncol. 2021;11:579351. https://doi.org/10.3389/fonc.2021.579351.

69.

Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911. https://doi.org/10.1136/jitc-2020-000911.

70.

Lecocq Q, Keyaerts M, Devoogdt N, Breckpot K. The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time’s a charm. Int J Mol Sci. 2020;22(1):75. https://doi.org/10.3390/ijms22010075.CrossRefPubMedPubMedCentral

71.

Mahne AE, Mauze S, Joyce-Shaikh B, et al. Dual roles for regulatory T-cell depletion and costimulatory signaling in agonistic GITR targeting for tumor immunotherapy. Cancer Res. 2017;77(5):1108–18. https://doi.org/10.1158/0008-5472.CAN-16-0797.CrossRefPubMed

72.

Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019;25(5):759–66. https://doi.org/10.1038/s41591-019-0420-8.CrossRefPubMedPubMedCentral

73.

Li DK, Wang W. Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies. Oncol Lett. 2020;20(5):176. https://doi.org/10.3892/ol.2020.12037.CrossRefPubMedPubMedCentral

74.

Byrne KT, Betts CB, Mick R, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res. 2021;27(16):4574–86. https://doi.org/10.1158/1078-0432.ccr-21-1047.CrossRefPubMedPubMedCentral

75.

Ansell SM, Flinn I, Taylor MH, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020;4(9):1917–26. https://doi.org/10.1182/bloodadvances.2019001079.CrossRefPubMedPubMedCentral

76.

Ven Kvd, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655–667. https://doi.org/10.2217/imt.15.32.

77.

Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014;211(4):715–25. https://doi.org/10.1084/jem.20130590.CrossRefPubMedPubMedCentral

78.

Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020;5(1):e000544. https://doi.org/10.1136/esmoopen-2019-000544.

79.

Jarr KU, Nakamoto R, Doan BH, et al. Effect of CD47 blockade on vascular inflammation. N Engl J Med. 2021;384(4):382–383. https://doi.org/10.1056/2FNEJMc2029834.

80.

Zhang W, Huang Q, Xiao W, et al. Advances in anti-tumor treatments targeting the CD47/SIRPα axis. Front Immunol. 2020;11:18. https://doi.org/10.3389/fimmu.2020.00018.CrossRefPubMedPubMedCentral

81.

Kojima Y, Volkmer JP, McKenna K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86–90. https://doi.org/10.1038/nature18935.CrossRefPubMedPubMedCentral

82.

Flores AM, Hosseini-Nassab N, Jarr KU, et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat Nanotechnol. 2020;15(2):154–61. https://doi.org/10.1038/s41565-019-0619-3.CrossRefPubMedPubMedCentral

83.

Engelbertsen D, Autio A, Verwilligen RAF, et al. Increased lymphocyte activation and atherosclerosis in CD47-deficient mice. Sci Rep. 2019;9:10608. https://doi.org/10.1038/s41598-019-46942-x.CrossRefPubMedPubMedCentral

84.

Ng SJ, Lau HC, Naseer R, et al. Atherosclerosis imaging: positron emission tomography. PET Clin. 2023;18(1):71–80. https://doi.org/10.1016/j.cpet.2022.09.004.CrossRefPubMed

85.

Poels K, Schreurs M, Jansen M, et al. Immuno-PET imaging of atherosclerotic plaques with [89Zr]Zr-Anti-CD40 mAb-proof of concept. Biology (Basel). 2022;11(3):408. https://doi.org/10.3390/biology11030408.CrossRefPubMed

86.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/nejmoa1615664.CrossRefPubMed

Titel: An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors
verfasst von: Judah M. Ellison
Anju Nohria
Publikationsdatum: 03.07.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 8/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01908-4

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Clinical Features of Takotsubo Syndrome and Its Differential Diagnostic Criteria in Clinical Nursing Practice: A Review of the Literature

Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer

COVID-19 and Acute Cardiac Injury: Clinical Manifestations, Biomarkers, Mechanisms, Diagnosis, and Treatment

Correction to: Echo Doppler Parameters of Diastolic Function

Supplements for Lipid Lowering: What Does the Evidence Show?

Incidence and Prevalence of Atrial Fibrillation in Latinos: What’s New Since the Study in Latinos (SOL)?

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie